November 25, 2022
Juran Kato, PhD, founder, president and CEO of GEXVal ., will give a presentation at an event organized by Link-J (Life Science Innovation Network Japan) held on November 28,2022.
This event is the third in the "Let's Talk with VCs" series, and we will be speaking on "The Realities of Clinical Trials in Australia: How Japanese Biotech Ventures are Making Inroads into the Country".
In recent years, early-stage clinical trials in Australia have been attracting attention, and are being actively utilized, especially by Asian, European, and American ventures. On the other hand, there are very few examples of their use in Japanese bio ventures. GEXVal has been in Phase I trials in Australia since July. GEXVal has also been featured by the South Australian government as the first Japanese bio-venture to establish a presence in the state.
In her presentation, she will talk about the process of the establishment of GEXVal, and the process of preparing for the clinical trial, and the realities that led to its implementation.
GEXVal strives to generate extra value to deliver cost-effective, innovative treatment options to improve health and QoL of patients and families affected by rare and intractable diseases.
For further information, please contact us: firstname.lastname@example.org